Thrombospondin-1 polymorphisms influence risk of corneal allograft rejection

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 4, 2014, Pages 2115-2120

  Winton, Helen L ^a   Bidwell, Jeffrey L ^b   Armitage, W John ^a  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Corneal transplantation; Single nucleotide polymorphism; Thrombospondin 1

Indexed keywords

GENOMIC DNA; HETERODUPLEX; HLA ANTIGEN CLASS 2; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN;

ADULT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; CORNEA TRANSPLANTATION; CORNEAL ALLOGRAFT REJECTION; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RNA STRUCTURE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

CORNEAL TRANSPLANTATION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSPONDIN-1;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ALLOGRAFTS; CORNEAL DISEASES; CORNEAL TRANSPLANTATION; DNA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; THROMBOSPONDIN 1; YOUNG ADULT;

EID: 84898715957     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13681     Document Type: Article

References (61)

1. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res. 2007;32:1005-1016.
2. Waldock A, Cook SD. Corneal transplantation: how successful are we? Br J Ophthalmol. 2000;84:813-815.
3. Hori J. Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation. J Ocul Biol Dis Inform. 2008;1:94-100.
4. Hori J, Vega JL, Masli S. Review of ocular immune privilege in the year 2010: modifying the immune privilege of the eye. Ocul Immunol Inflamm. 2010;18:325-333.
5. Niederkorn JY, Larkin DFP. Immune privilege of corneal allografts. Ocul Immunol Inflamm. 2010;18:162-171.
6. Williams KA, Coster DJ. The immunobiology of corneal transplantation. Transplantation. 2007;84:806-813.
7. Taylor AW. Ocular immunosuppressive microenvironment. Chem Immunol Allergy. 2007;92:71-85.
8. Denniston AK, Kottoor SH, Khan I, et al. Endogenous cortisol and TGF-beta in human aqueous humor contribute to ocular immune privilege by regulating dendritic cell function. J Immunol. 2011;186:305-311.
9. Taylor AW, Yee DG, Streilein JW. Suppression of nitric oxide generated by inflammatory microphages by calcitonin generelated peptide in aqueous humor. Invest Ophthalmol Vis Sci. 1998;39:1372-1378.
10. Streilein JW, Masli S, Takeuchi M, Kezuka T. The eye's view of antigen presentation. Hum Immunol. 2002;63:435-443.
11. Wilbanks GA, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). 3. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol. 1992;22:165-173.
12. Coster DJ, Williams KA. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation. Am J Ophthalmol. 2005;140:1112-1122.
13. Williams KA, Muehlberg SM, Lewis RF, Coster DJ. How successful is corneal transplantation? A report from the Australian Corneal Graft Register. Eye. 1995;9:219-227.
14. Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival-report from the Australian Corneal Graft Registry. Ophthalmology. 1992;99: 403-414.
15. Cursiefen C, Maruyama K, Bock F, et al. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med. 2011;208:1083-1092.
16. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD. Thrombospondin-1 inhibits VEGF Receptor-2 signaling by disrupting its association with CD47. J Biol Chem. 2010;285:38923-38932.
17. Qin LL, Zhao DZ, Xu JF, et al. The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. Blood. 2013;121:2154-2164.
18. Wolf FW, Eddy RL, Shows TB, Dixit VM. Structure and chromosomal localization of the human thrombospondin gene. Genomics. 1990;6:685-691.
19. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004;36:961-968.
20. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta 1 in vivo. Cell. 1998; 93:1159-1170.
21. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 1991;32:2201-2211.
22. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and-2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004;45:1117-1124.
23. Sekiyama E, Nakamura T, Cooper LJ, et al. Unique distribution of thrombospondin-1 in human ocular surface epithelium. Invest Ophthalmol Vis Sci. 2006;47:1352-1358.
24. Hiscott P, Paraoan L, Choudhary A, Ordonez JL, Al-Khaier A, Armstrong DJ. Thrombospondin 1, thrombospondin 2 and the eye. Prog Ret Eye Res. 2006;25:1-18.
25. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6:41-48.
26. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis-evidence, mechanisms, and implications for corneal transplant immunology. Cornea. 2003;22:273-281.
27. Schultz-Cherry S, Chen H, Mosher DF, et al. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin-1. J Biol Chem. 1995;270:7304-7310.
28. Larkin DF, Alexander RA, Cree IA. Infiltrating inflammatory cell phenotypes and apoptosis in rejected human corneal allografts. Eye. 1997;11:68-74.
29. Kuffova L, Holan V, Lumsden L, Forrester JV, Filipec M. Cell subpopulations in failed human corneal grafts. Br J Ophthalmol. 1999;83:1364-1369.
30. Yamagami S, Ebihara N, Usui T, Yokoo S, Amano SO. Bone marrow-derived cells in normal human corneal stroma. Arch Ophthalmol. 2006;124:62-69.
31. Shen LL, Barabino S, Taylor AW, Dana R. Effect of the ocular microenvironment in regulating corneal dendritic cell maturation. Arch Ophthalmol. 2007;125:908-915.
32. Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW. Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci. 2005;46:908-919.
33. Maier P, Broszinski A, Heizmann U, Reinhard T. Decreased active TGF-beta 2 levels in the aqueous humour during immune reactions following penetrating keratoplasty. Eye. 2008;22: 569-575.
34. Reinhard T, Bonig H, Mayweg S, Bojhringer D, Gobel U, Sundmacher R. Soluble Fas ligand and transforming growth factor beta(2) in the aqueous humor of patients with endothelial immune reactions after penetrating keratoplasty. Arch Ophthalmol. 2002;120:1630-1635.
35. Maier P, Broszinski A, Heizmann U, Bohringer D, Reinhard T. Active transforming growth factor-beta(2) is increased in the aqueous humor of keratoconus patients. Mol Vis. 2007;13: 1198-1202.
36. Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA, Armitage WJ. Conclusions of the corneal transplant follow up study. Br J Ophthalmol. 1997;81:631-636.
37. Wood NAP, Keen LJ, Tilley LA, Bidwell JL. Determination of cytokine regulatory haplotypes by induced heteroduplex analysis of DNA. J Immunol Meth. 2001;249:191-198.
38. De Bakker PIW, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nature Genet. 2005;37:1217-1223.
39. Altshuler D, Brooks LD, Chakravarti A, et al. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
40. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21:263-265.
41. Rozen SSH. Primer3 on the WWW for General Users and for Biologist Programmers. Totowa NJ: Humana Press; 2000.
42. Mathews DH, Disney MD, Childs JL, Schroeder SJ, Zuker M, Turner DH. Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci U S A. 2004;101:7287-7292.
43. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health. Version 2.3.1. Available at: http://www.openepi.com/oe2.3/menu/ openepimenu.htm. Accessed March 10, 2010.
44. Lowry R. Website for statistical computation. Available at: http://wwwvassarstatsnet. Accessed March 10, 2010.
45. Christensen K. Available at: http://wwwhusdyrkvldk/htm/kc/ popgen/genetik/applets/kitesthtm. Accessed March 10, 2010.
46. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
47. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73:1162-1169.
48. Bonferroni CE. Teoria statistica delle classi e calcolo delle probabilita. Pubblicatiozioni del R Instituto Superiore de Scienze Economiche a Commerciali di Firenze. 1936;8:3-62.
49. Schneider S, Roessli D, Excoffier L. Arlequin: a software for population genetics data analysis. Available at: http://www. ncbi.nlm.nih.gov/pmc/articles/PMC2658868/. Ver 2.000. Accessed March 10, 2010.
50. Barrett LW, Fletcher S, Wilton SD. Regulation of eukaryotic gene expression by the untranslated gene regions and other noncoding elements. Cell Mol Life Sci. 2012;69:3613-3634.
51. AshokKumar M, Anbarasan C, SaiBabu R, Kuram S, Raman SC, Cherian KM. An association study of thrombospondin 1 and 2 SNPs with coronary artery disease and myocardial infarction among South Indians. Thromb Res. 2011;128:E49-E53.
52. Masli S, Turpie B, Streilein JW. Thrombospondin orchestrates the tolerance-promoting properties of TGF beta-treated antigen-presenting cells. Int Immunol. 2006;18:689-699.
53. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and-2. Int J Biochem Cell Biol. 2004;36: 1038-1045.
54. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040-1050.
55. Turpie B, Yoshimura T, Gulati A, Rios JD, Dartt DA, Masli S. Sjogren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Path. 2009;175:1136-1147.
56. Saban DR, Bock F, Chauhan SK, Masli S, Dana R. Thrombospondin-1 derived from APCs regulates their capacity for allosensitization. J Immunol. 2010;185:4691-4697.
57. Camelo S, Kezic J, McMenamin PG. Anterior chamber-associated immune deviation: a review of the anatomical evidence for the afferent arm of this unusual experimental model of ocular immune responses. Clin Exp Ophthal. 2005;33:426-432.
58. Camelo S, Kezic J, Shanley A, Rigby P, McMenamin PG. Antigen from the anterior chamber of the eye travels in a soluble form to secondary lymphoid organs via lymphatic and vascular routes. Invest Ophthalmol Vis Sci. 2006;47:1039-1046.
59. Mallakin A, Sugiyama T, Kai F, et al. The Arf-inducing transcription factor Dmp1 encodes a transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1. Int J Cancer. 2010;126:1403-1416.
60. Taneja P, Mallakin A, Matise LA, Frazier DP, Choudhary M, Inoue K. Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-kappa B subunit p65. Oncogene. 2007; 26:7457-7466.
61. De Stefano D, Nicolaus G, Maiuri MC, et al. NF-kappa B blockade upregulates Bax, TSP-1, and TSP-2 expression in rat granulation tissue. J Mol Med. 2009;87:481-492.